Radiomic features based on pyradiomics predict CD276 expression associated with breast cancer prognosis
Author:
Li YongORCID,
Chen Chun-mei,
Li Wei-wen,
Shao Ming-tao,
Dong Yan,
Zhang Qun-chen
Reference25 articles.
1. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study;Fitzmaurice;JAMA Oncol.,2018
2. Targeting PD-1/PD-L1 in cancer immunotherapy: an effective strategy for treatment of triple-negative breast cancer (TNBC) patients;Kumar;Genes Dis,2023
3. Global research trends on B7-H3 for cancer immunotherapy: a bibliometric analysis (2012-2022);Huang;Hum. Vaccines Immunother.,2023
4. Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy;Zhao;J. Hematol. Oncol.,2022
5. Preclinical development of MGC018, a duocarmycin-based antibody-drug conjugate targeting B7-H3 for solid cancer;Scribner;Mol. Cancer Therapeut.,2020